The European Commission (EC) has approved Johnson & Johnson’s Tecvayli (teclistamab) plus daratumumab for relapsed/refractory multiple myeloma, offering a potential new standard of care. The indication extension in combination with daratumumab is approved for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior therapy. Teclistamab and […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!